First-in-human response of BCL-2 inhibitor venetoclax in T-cell prolymphocytic leukemia

MLA

Boidol, Bernd, et al. “First-in-Human Response of BCL-2 Inhibitor Venetoclax in T-Cell Prolymphocytic Leukemia.” Blood, vol. 130, no. 23, Dec. 2017, pp. 2499–503. EBSCOhost, https://doi.org/10.1182/blood-2017-05-785683.

APA

Boidol, B., Kornauth, C., van der Kouwe, E., Prutsch, N., Kazianka, L., Gültekin, S., Hoermann, G., Mayerhoefer, M. E., Hopfinger, G., Hauswirth, A., Panny, M., Aretin, M.-B., Hilgarth, B., Sperr, W. R., Valent, P., Simonitsch-Klupp, I., Moriggl, R., Merkel, O., Kenner, L., … Staber, P. B. (2017). First-in-human response of BCL-2 inhibitor venetoclax in T-cell prolymphocytic leukemia. Blood, 130(23), 2499–2503. https://doi.org/10.1182/blood-2017-05-785683

Chicago

Boidol, Bernd, Christoph Kornauth, Emiel van der Kouwe, Nicole Prutsch, Lukas Kazianka, Sinan Gültekin, Gregor Hoermann, et al. 2017. “First-in-Human Response of BCL-2 Inhibitor Venetoclax in T-Cell Prolymphocytic Leukemia.” Blood 130 (23): 2499–2503. doi:10.1182/blood-2017-05-785683.